Age-related macular degeneration (ARMD) – Related resources

Cochrane reviews

  • Interferon alfa-2a appears not to be beneficial for the treatment of age-related macular degeneration and may even have harmful effects [Evidence Level: B].
  • Vitamin E or beta-carotene supplements will not prevent or delay the onset of age-related macular degeneration [Evidence Level: A].
  • There is insufficient evidence on the benefits and harms of steroids with antiangiogenic properties for treating neovascular age-related macular degeneration [Evidence Level: D].
  • Surgical removal of choroidal neovascularisation in patients with subfoveal choroidal neovascularisation due to age-related macular degeneration does not prevent visual loss compared to observation, and the risk of developing cataract and retinal detachment increases after surgery [Evidence Level: A].
  • Laser photocoagulation of drusen appears no to reduce the risk of developing choroidal neovascularisation, geographic atrophy, or visual acuity loss [Evidence Level: B].
  • Statins seem to have no effect on the onset or progression of age-related macular degeneration, although the evidence is insufficient [Evidence Level: D].

Literature

Clinical practice reviews

  • Coleman HR, Chan CC, Ferris FL 3rd, Chew EY. Age-related macular degeneration. Lancet 2008 Nov 22;372(9652):1835-45.  [PMID:19027484]

Other literature

  • Folk JC, Stone EM. Ranibizumab therapy for neovascular age-related macular degeneration. N Engl J Med 2010 Oct 21;363(17):1648-55.  [PMID:20961248]


Copyright © 2017 Duodecim Medical Publications Limited.
Age-related macular degeneration (ARMD) – Related resources is a sample topic from the Evidence-Based Medicine Guidelines.

To view other topics, please or purchase a subscription.

Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Complete Product Information.